
|Articles|October 1, 2003
Bexarotene Therapy
Chicago - Results of two clinical trials involving bexarotene (Targretin) and presented at recent meetings of the American Academy of Dermatology offer hope for patients with severe forms of psoriasis refractory to systemic therapies, according to researchers.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Delgocitinib Advances to Phase 3 Evaluation for Lichen Sclerosus
2
The “6-7” Advances for Dermatologists to Look Forward to in 2026
3
Obagi Launches ALOHA Program to Capture Real-World Insights in Aesthetic Injectables
4
Quoin Targets World’s First Approval for Netherton Syndrome Therapy in Saudi Arabia
5



















